# Lineagen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lineagen

- Industry: Biotechnology
- Headquarters: Salt Lake City, US
- Website: www.lineagen.com
- Total disclosed funding: $54M
- Latest round: Series C (Jan 9, 2015)
- Investors on record: 13

## About

Lineagen Inc. is a healthcare company focused on providing advanced genetic testing and analysis services, particularly for pediatric neurodevelopmental disorders, enhancing clinical decision-making for healthcare providers.Lineagen Inc. was founded in 2002 and is headquartered in Salt Lake City, US. The company specializes in genetic testing services aimed at understanding pediatric neurodevelopmental disorders. In August 2020, Lineagen was acquired by BioNano Genomics, Inc. for USD 9.6 million. The company has successfully completed 9 funding deals to date, with the most recent being a Trade Sale. The total amount raised by Lineagen amounts to USD 9.6 million, all secured through their latest funding round.Lineagen, Inc. specializes in advanced genetic testing and analysis services, particularly targeting pediatric neurodevelopmental disorders such as autism spectrum disorder and developmental delays. Their core offerings include a range of genetic tests, such as the FirstStep Dx PLUS Chromosomal Microarray and NextStep Dx PLUS Whole Exome Sequencing, which provide vital clinical insights for healthcare providers. Additionally, they offer Optical Genome Mapping (OGM) services, facilitating research into structural variations in the genome, catering to both clinicians and researchers exploring genetic implications in various medical conditions. Lineagen primarily serves markets in North America, expanding its reach to other international territories as demand for genetic testing increases.Lineagen's revenue model relies on direct transactions with healthcare providers and researchers seeking genetic testing services for their patients or studies. The company engages in B2B transactions, offering specialized genetic testing solutions including flagship products like the OGM-Dx series for postnatal and prenatal testing. They have established flexible pricing structures catering to various scales of testing, ensuring accessibility for both large institutions and individual practitioners. The ordering process is designed to facilitate ease of access to their offerings, ensuring a smooth experience from initial consultation to result delivery. By focusing on high-quality, advanced genetic analysis, Lineagen effectively meets the needs of its clients while driving revenue through these tailored testing services.Following the acquisition by BioNano Genomics, Inc. in August 2020, Lineagen is expected to leverage its new resources to enhance its product offerings and expand into new markets. The company is actively developing new genetic testing products aimed at further improving clinical outcomes in pediatric healthcare. Additionally, plans are underway to enter new geographic regions to meet the growing demand for genetic testing services. The funding obtained through the recent acquisition will support these initiatives, focusing on product development and market expansion.

## Funding rounds

- Series C, Jan 9, 2015, $12M — Petra Capital Partners, Sanderling Ventures, Sofinnova Investments, University Venture Fund, Signal Peak Ventures, Mesa Verde Venture Partners, PrairieGold Venture Partners, Mountain Group Partners, Kickstart Ventures, HealthQuest Capital, Archipel Capital
- Series C, Nov 9, 2013, $16M — Sanderling Ventures, University Venture Fund, Signal Peak Ventures, Mesa Verde Venture Partners, Hatteras Venture Partners, PrairieGold Venture Partners, Kickstart
- Series B, Oct 4, 2010, $15M — Sanderling Ventures, Signal Peak Ventures, Mesa Verde Venture Partners, PrairieGold Venture Partners
- Series A, May 28, 2010, $5M — Sanderling Ventures, Signal Peak Ventures, Mesa Verde Venture Partners, PrairieGold Venture Partners
- Series A, Oct 12, 2007, $5.7M — Sanderling Ventures, Signal Peak Ventures, Mesa Verde Venture Partners

## Investors

- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series A, Series B, Series C
- Signal Peak Ventures (https://capitalatlas.ai/funds/signal-peak-ventures) — Series A, Series B, Series C
- Mesa Verde Venture Partners (https://capitalatlas.ai/funds/mesa-verde-venture-partners) — Series A, Series B, Series C
- PrairieGold Venture Partners (https://capitalatlas.ai/funds/prairiegold-venture-partners) — Series A, Series B, Series C
- University Venture Fund (https://capitalatlas.ai/funds/university-venture-fund) — Series C
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series C
- Kickstart (https://capitalatlas.ai/funds/kickstart) — Series C
- Petra Capital Partners (https://capitalatlas.ai/funds/petra-capital-partners) — Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series C
- Mountain Group Partners (https://capitalatlas.ai/funds/mountain-group-partners) — Series C
- Kickstart Ventures (https://capitalatlas.ai/funds/kickstart-ventures) — Series C
- HealthQuest Capital (https://capitalatlas.ai/funds/healthquest-capital) — Series C
- Archipel Capital (https://capitalatlas.ai/funds/archipel-capital) — Series C